Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BDNF


Brief Information

Name:Brain-derived neurotrophic factor
Target Synonym:Brain-Derived Neurotrophic Factor,Abrineurin,ANON2,Brain Derived Neurotrophic Factor,BULN2,ProBDNF,Neurotrophin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
BDF-H5219 Human Human BDNF / Abrineurin Protein, premium grade
ACRO Quality

Part of Bioactivity data


Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 1 μg/mL (100 μL/well) can bind Human TrkB, His Tag (Cat. No. NT2-H5228) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name



Brain-derived neurotrophic factor (BDNF) along with nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin family of trophic factors. The neurotrophins play essential roles in the development, survival, and function of a wide range of neurons in both the peripheral and central nervous systems. The neurotrophins interact with two cell surface receptors, the low affinity P75 receptor and the Trk family of high affinity tyrosine kinase receptors. NGF preferentially binds TrkA, BDNF and NT4/5 bind TrkB, and NT-3 binds TrkC (and TrkA to a lesser extent).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Laquinimod Sodium SAIK-MS; TV-5600; ABR-215062 Approved Active Biotech Ab Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Huntington Disease; Uveitis; Arthritis; Eye Diseases; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tetramethylpyrazine Nitrone Phase 3 Clinical Jinan University Diabetes Mellitus, Type 2; Stroke; Diabetic Nephropathies; Amyotrophic Lateral Sclerosis Details
ACT-01 ACT-01; OCS-05; BN-201; G-79 Phase 2 Clinical Promius Pharma Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases Details
MP-101 MP101; MP-101 Phase 2 Clinical Mitochon Pharmaceuticals Multiple Sclerosis; Huntington Disease; Amyotrophic Lateral Sclerosis Details
ALTO-100 ALTO-100 Phase 2 Clinical Alto Neuroscience Inc Depressive Disorder, Major; Stress Disorders, Post-Traumatic Details
AC-102 AC-102 Phase 2 Clinical AudioCure Pharma GmbH Tinnitus; Hearing Loss, Sensorineural; Hearing Loss, Sudden Details
TTI-0102 TTI-0102 Phase 2 Clinical Va Office Of Research And Development Coronavirus Disease 2019 (COVID-19); Stress Disorders, Post-Traumatic Details
JS1-1-01 JS1-1-01 Phase 2 Clinical Tianjin Tasly Pharmaceutical Co Ltd Depressive Disorder, Major; Depression; Depressive Disorder Details
AAV2-BDNF gene therapy (University Of California San Diego) Phase 1 Clinical University Of California San Diego Alzheimer Disease; Cognitive Dysfunction Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message